Business Context and Reporting Period
Company: Outlook Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 14, 2019
Reporting Period: First fiscal quarter ended December 31, 2018.
Status: The registrant is an emerging growth company.
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the referenced press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The filing does not contain specific data to compare current period performance against prior periods. It solely references the announcement of Q4 2018 results.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on February 14, 2019, announcing its financial results for the quarter ended December 31, 2018.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific financial figures for the quarter ended December 31, 2018.
- Verify the company's cash runway and burn rate, as these are critical for a pre-revenue or early-stage biotech firm.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.
- Check for any subsequent filings that may incorporate the press release data by reference.